with age and the slightly higher levels of plasma calcium often found after the menopause (Young and Nordin, 1967) .
We therefore conclude that the failure of urinary Ca/Cr and calcium to rise after late evening calcium supplements as much in the postmenopausal as in the premenopausal women may well be due to a greater effect in the former group of suppression of nocturnal bone dissolution, as outlined above.
Not consistent with this hypothesis is the recent finding of Jubiz et al. (1972) that the normal rise of plasma parathormone which occurs in the early hours of the morning cannot be suppressed by an overnight intravenous infusion of calcium sufficient to raise the plasma calcium to about 11-0 mg/100 ml. This observation was confined to two young subjects and requires further confirmation, and its significance is in any case rendered uncertain by current difficulties in the understanding of the relation of parathormone immunoassay measurements to biological activity (Parsons and Potts, 1972) . Thus, Reiss (1970) could detect little fall of serum immunoreactive parathormone after calcium infusion in patients with parathyroid adenomas, whereas Potts et al. (1971) G., 1967 ) has led to a search for alternative forms of oestrogen therapy. Kaplan (1968) suggested that conjugated equine oestrogens (Premarin) might prove more satisfactory than stilboestrol. More recently Byar (1972) reported the findings of the second V.A.U.C.R.G. that 1 mg diethylstiluboestrol daily was equally effective against the cancer while apparently free from the cardiovascular complications of the larger dose.
Patients with carcinoma of the prostate are usually elderly and might be expected to show abnormalities of blood lipids and carbohydrate tolerance (Boyns et al., 1969) . Furthermore, synthetic oestrogens have been shown to raise plasma triglyceride levels (Hazzard et al., 1969) and produce carbohydrate intolerance (Wynn and Doar, 1966) . These abnormalities have been shown to be associated with an increased risk of atherosclerosis (Wahlberg and Thomasson, 1968) . The present study was undertaken to compare the effects of different doses of stilboestrol and of Premarin on blood lipids and glucose tolerance in patients with carcinoma of the prostate.
Patients and Methods
Sixteen patients with histologically-proved carcinoma of the prostate were studied whose ages ranged from (mean 71) years. All the patients had had the nature of the study explained to them and had agreed to take part. Oestrogen treatment was with stilboestrol in doses of 1, 7 Serum Triglycerides.-Raised levels of serum triglycerides were found in most of the patients while taking stilboestrol 75 mg and 15 mg daily and Premarin 15 mg daily, and in one subject the levels were considerably raised throughout the study (fig. 2) . In six out of 10 patients who received stilboestrol 1 mg daily, however, the levels remained within the normal range. In one patient raised serum triglycerides were found before starting oestrogen treatment. Mean serum triglyceride levels were significantly raised in those on stilboestrol 7 5 mg daily (P < 0-005) and 15 mg daily (P < 0 02) and Premarin (P < 0-005) as compared with patients before oestrogen therapy, but not in those on 1 mg stilboestrol daily (P > 0 4). The rise in serum triglyceride levels, when occurring, was observed within six weeks of starting oestrogens, and thereafter serum levels remained stationary.
Lipoprotein Electrophoresis.-Oestrogen therapy in all dose levels caused a rise in a-lipoproteins. In those patients who showed a rise in serum triglycerides an increase in pre-I3-lipoproteins was usually seen.
Glucose Tolerance (fig. 3 ).-There was no difference between the results of the tests in those patients receiving the different oestrogen regimens as compared with each other nor with those before oestrogen treatment ( fig. 3 ). Impaired glucose tolerance was found in four patients, one of whom was frankly diabetic. Antitumour Eflect. Acid and Alkaline Phosphatase.-There was no apparent difference in response to treatment between the different oestrogen regimens. Three patients with bony metastasis, two of whom subsequently died, had persistently normal acid phosphatase but raised alkaline phosphatase levels.
Calcium and Phosphorus.-There was no difference between calcium and phosphorus levels in the different oestrogen regimens. There were too few pretreatment estimations to allow comparison with the effect of treatment.
Discussion
There is much controversy as to the most satisfactory form of oestrogen therapy for patients with carcinoma of the prostate (Fergusson, 1970) . This dilemma has been highlighted by the first V.A.U.C.R.G.'s study (1967) , which suggested that deaths from cardiovascular causes outweighed the antitumour effects of diethylstilboestrol when given in a dose of 5 mg daily. Synthetic oestrogens are known to raise serum very-low density lipoproteins (Furman, 1969) and to cause changes in the platelet response to adenosine diphosphate (Bolton et al., 1967) . These effects may be of importance with regard to the observed increased cardiovascular mortality. In the second V.A.U.C.R.G.'s study no such increase in cardiovascular deaths was found when diethylstilboestrol in a dose of 1 mg daily was used, although its antitumour effect was comparable to the larger dose (Byar, 1972) .
In the present investigation all the patients receiving di- (Marmorston and Griffith, 1964) . Nevertheless, Premarin in a dose of 15 mg daily, which is about equal in oestrogenic effect to 6 mg of diethylstilboestrol (Israel, 1967) , also produced a consistent rise of serum triglycerides. In our study no effect on serum cholesterol was found in the different treatment groups although others have found stilboestrol and Premarin (Robinson et al., 1963) to produce a small reduction of serum levels. Glucose intolerance was found in only four patients, rather surprisingly in view of the age of the patients and the high doses of oestrogens used, and only one patient was frankly diabetic. There was no difference in the incidence of glucose intolerance between the different treatment regimens.
In one of the few studies of serum lipids and glucose tolerance in prostatic cancer patients reported Sontaniemi (1970, 1971) found that doses of stilboestrol diphosphate of 200-500 mrg daily produced a noticeable rise in serum triglycerides, and induced glucose intolerance in some of their patients. Meissner and Moehring (1960) , however, were unable to show any changes in serum lipids or postmortem evidence of increased atherosclerosis in a group of prostatic cancer patients treated with unspecified oestrogens.
The raised levels of serum triglycerides produced by high doses of diethylstilboestrol and Premarin and the absence of these changes using stilboestrol 1 mg daily supports the suggestion that this lower dose of stilboestrol should regularly be used in the treatment of patients with carcinoma of the prostate (Byar, 1972) .
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